Press Room


    Press Release - July 19, 2006

    Pheromone Builds Scientific Advisory Board: Appoints Dr. Norman Wong to Help Develop Diabetes Product

    Kelowna, B.C. - Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. Norman Wong, M.D., F.R.C.P.(C), has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

    "With extensive experience in researching and treating diabetes mellitus, Dr. Wong is an important addition to our Scientific Advisory Board," stated Dr. David White, Chair of Pheromone's SAB. "His medical career has demonstrated both his commitment to the treatment of diabetes and his ability to commercialize research findings."

    Dr. Wong is the co-founder of Resverlogix Corp. (TSX: RVX) and serves as the Chairman of its SAB. He is also the Director of the Libin Gene Therapy Unit and is a Professor in both the departments of Medicine and Biochemistry & Molecular Biology at the University of Calgary.

    About Dr. Wong Dr. Wong graduated from the University of Calgary, Faculty of Medicine in 1980, completed his internal medicine residency in 1983, and then received his fellowship training in endocrinology at the University of Minnesota. His research interest deals primarily with the molecular actions of hormones and specifically that related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. He has published numerous articles in the field of diabetes research. His clinical interest encompasses patients with diabetes mellitus or thyroid disease. In addition to his current positions, he has previously held posts at the University of Calgary. as Associate Vice-President of Research and International, and Assistant Dean (Research) Faculty of Medicine.

    About the Diabetes Research Project Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Currently approved transplant procedures for reversing diabetes are rarely used because of the lack of suitable human organ donors and the need for patients to use immune suppressing anti-rejection drugs for the rest of their lives. Pheromone is in the process of developing a procedure to overcome these limitations by inserting into an implantable device two types of pig cells: islet cells that produce insulin compatible with humans, and Sertoli cells which will naturally protect the islet cells from attack by the body's immune system.

    Using rigorous and widely accepted scientific experimentation methods, Pheromone's goal is to receive approval for this cellular therapy product from the United States Food and Drug Administration, and from other national regulatory bodies throughout the world. The research is based on several proof-of-concept studies completed by Dr. David White, Pheromone's principal researcher, and others. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

    Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.


    "Dev Randhawa"

    Dev Randhawa, CEO

    For further information contact:

    Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News